Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 1997

View Archived Issues

Hair growth stimulants from Tanabe

Nisshin Flour Milling claims antidiabetic compounds

Company Profile: DepoTech Corp.

Novel myocardial protectant described by Taiwanese researchers

Searle describes new platelet aggregation inhibitors

New psychopharmacological agents developed by Ferrer

Novel allergy agent claimed by French researchers

GRF analogues developed for growth hormone deficiencies

COX-2 inhibitors reported by Merck Frosst

Pharmacia & Upjohn claims camptothecin derivatives

Antibacterial and antineoplastic agents developed by Abbott

Thrombin inhibitors from BioChem Pharma

RPR discloses novel polypeptides for cancer

Spotlight on influenza sialidase inhibitors

Novartis selects analgesic agent as clinical candidate

Korean investigators isolate natural antioxidant

Orally active anti-PCP agents developed by U.S. investigators

Enantiospecific synthesis of SP antagonist from RPR

Mediolanum prepares novel quinolone antibacterial agents

NAChR agonist SIB-1765F: Potential antiparkinsonian agent

Spanish pharmaceutical merger confirmed

Hypocholesterolemic activity of raloxifene established in rats

Voriconazole effective in guinea pig model of A. fumigatus endocarditis

Preliminary results for potential new anti-HIV combination presented

Combination HIV-IG/MAbs shows synergistic anti-HIV effects

Clinical data on AccuSite published in peer-reviewed journals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...